Literature DB >> 17205072

Primary CNS lymphoma.

Fred H Hochberg1, Joachim M Baehring, Ephraim P Hochberg.   

Abstract

Non-Hodgkin's lymphoma invades the brain, the vitreous body and nerves of the eye, the meninges, and the nerve roots of brain and spine, leading to the development of a primary CNS lymphoma. The mechanism of involvement of these locations by malignant B lymphocytes is unknown, but it might involve molecular targeting of lymphoma cells generated at cryptic systemic sites. The diagnosis of primary CNS lymphoma has been facilitated by advances in imaging techniques and the discovery of molecular markers. Methotrexate-based regimens, even when radiation is deferred, prolong overall survival to over 5 years, but relapses eventually occur in most cases. Better tools for earlier diagnosis and monitoring of treatment response will emerge from molecular studies of therapeutic targets.

Entities:  

Mesh:

Year:  2007        PMID: 17205072     DOI: 10.1038/ncpneuro0395

Source DB:  PubMed          Journal:  Nat Clin Pract Neurol        ISSN: 1745-834X


  32 in total

1.  Low frequency of blood group A in primary central nervous system lymphoma.

Authors:  Manouchehr Gharouni; Mehdi Abouzari; Armin Rashidi; Nasim Sodagari; Mehrdad Behzadi
Journal:  J Neurooncol       Date:  2008-01-22       Impact factor: 4.130

2.  Unusual presentation of anaplastic large cell lymphoma with clinical course mimicking fever of unknown origin and sepsis: autopsy study of five cases.

Authors:  Marina B Mosunjac; J Bruce Sundstrom; Mario I Mosunjac
Journal:  Croat Med J       Date:  2008-10       Impact factor: 1.351

Review 3.  Biology and treatment of primary central nervous system lymphoma.

Authors:  Alain P Algazi; Cigall Kadoch; James L Rubenstein
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

4.  Successful treatment of primary central nervous system lymphoma without irradiation in children: single center experience.

Authors:  Jong Hyung Yoon; Hyoung Jin Kang; Hyery Kim; Ji Won Lee; June Dong Park; Kyung Duk Park; Hee Young Shin; Hyo Seop Ahn
Journal:  J Korean Med Sci       Date:  2012-10-30       Impact factor: 2.153

5.  Combined diffusion and perfusion MR imaging as biomarkers of prognosis in immunocompetent patients with primary central nervous system lymphoma.

Authors:  F E Valles; C L Perez-Valles; S Regalado; R F Barajas; J L Rubenstein; S Cha
Journal:  AJNR Am J Neuroradiol       Date:  2012-08-30       Impact factor: 3.825

6.  The Combined Performance of ADC, CSF CXC Chemokine Ligand 13, and CSF Interleukin 10 in the Diagnosis of Central Nervous System Lymphoma.

Authors:  M C Mabray; R F Barajas; J E Villanueva-Meyer; C A Zhang; F E Valles; J L Rubenstein; S Cha
Journal:  AJNR Am J Neuroradiol       Date:  2015-09-17       Impact factor: 3.825

7.  Efficacy and Complications of Intravitreal Rituximab Injection for Treating Primary Vitreoretinal Lymphoma.

Authors:  Noriyasu Hashida; Nobuyuki Ohguro; Kohji Nishida
Journal:  Transl Vis Sci Technol       Date:  2012-10-22       Impact factor: 3.283

8.  Unusual cause of dementia in an immunocompetent host: toxoplasmic encephalitis.

Authors:  Mario Habek; David Ozretić; Kamelija Zarković; Visnja Djaković; Zdenko Mubrin
Journal:  Neurol Sci       Date:  2009-01-16       Impact factor: 3.307

9.  Association between ocular findings and preventive therapy with onset of central nervous system involvement in patients with primary vitreoretinal lymphoma.

Authors:  Noriyasu Hashida; Kei Nakai; Norimitsu Saitoh; Kohji Nishida
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-02-19       Impact factor: 3.117

10.  Pathologic correlates of primary central nervous system lymphoma defined in an orthotopic xenograft model.

Authors:  Cigall Kadoch; Eduard B Dinca; Ramona Voicu; Lingjing Chen; Diana Nguyen; Seema Parikh; Juliana Karrim; Marc A Shuman; Clifford A Lowell; Patrick A Treseler; C David James; James L Rubenstein
Journal:  Clin Cancer Res       Date:  2009-03-10       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.